Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Technological platforms boost European cardiovascular research

13.12.2006
Proteomics, bioinformatics and Zebrafish are the novel tools set up by the European Vascular Genomics Network (EVGN).

Advanced technology is crucial to today’s biomedical research. But it is expensive and it requires specific expertise, which is expensive too. Then sharing becomes a must. And it guarantees a high level of cooperation among research groups throughout Europe. In 2006, the European Vascular Genomics Network (EVGN), a Network of Excellence funded by the European Union within its 6th Framework Programme, has launched three platforms, all of them representing cutting edge tools in the field of cardiovascular science and aimed at strengthening and improving the research effectiveness of the Network. The platforms were presented during the Third EVGN annual Conference (Toulouse, 11-14 December 2006).

The Zebrafish platform (Zebrafish, the fish Danio rerio, is an extremely versatile model organism in modern molecular biology) intends to provide EVGN scientists with a direct access to the Zebrafish model system for in vivo studies of cardiovascular development and disease. The Zebrafish platform is based at IFOM, the FIRC Institute of Molecular Oncology (Milan, Italy) and it is led by EVGN scientist Marina Mione.

The bioinformatics platform will provide EVGN researchers with a comprehensive set of software and web tools for storing, accessing, analyzing and elaborating the huge amount of data that comes from today’s high throughput technologies (in particular, gene and protein expression data). The platform is managed by Anton Horrevoets of the Academisch Medisch Centrum (University of Amsterdam).

Last but not least, an innovative proteomic platform has been launched, to perform advanced studies on structure and function of the proteins involved in the process of formation and development of cardiovascular disease. The promise of proteomics in this field is to carry out large scale-studies of gene expression at the protein level, providing the basis for a detailed understanding of pathophysiological mechanisms and leading to the discovery of potential targets for drug development. The EVGN proteomic platform is managed by Manuel Mayr, of the St George's Hospital Medical School (London, UK).

“EVGN platforms – explains EVGN scientific coordinator Alain Tedgui, of Inserm, Paris – represent essential tools to our network. These technologies are necessary for today’s research, but they are extremely expensive, and would not be affordable for individual institutes. Also, every platform requires specific and advanced expertise, and this is expensive too. Sharing human and technological resources becomes then crucial. Also, having common platforms guarantees that we all work with experts with both highly specific expertise and a solid background in cardiovascular disease.” More than being just core facilities, the EVGN platforms base their work on collaborative projects. “The scientists who work at the platforms – adds Tedgui – are not technicians, they are indeed involved in collaborative projects with several EVGN partners.”

The future of EVGN

EVGN, which was launched in 2004, will be active until the end of 2008. But its legacy will be taken on by new specific projects to be activated during the 7th Framework Programme. “What we have done here, with EVGN, was to lay the foundations of European vascular disease with a highly collaborative approach. Now we need to go on. Some of the area that will be covered by the new Programme – says Tedgui – will directly interest EVGN members. For example inflammatory and vascular remodelling, or stem cells in ischemic disease. Several groups and leaders of EVGN will join together and propose innovative actions in these fields of research.”

The European Vascular Genomics Network (EVGN) is the first Network of excellence on cardiovascular disease funded by the European Commission under the 6th Framework Programme "Life sciences, genomics and biotechnology for health" (Contract Number: LSHM-CT-2003-503254).

The Third EVGN Annual Conference is supported by an unrestricted educational grant from Laboratoires SERVIER.

Francesca Noceti | alfa
Further information:
http://www.ifom-ieo-campus.it
http://www.evgn.org

Further reports about: Cardiovascular EVGN expensive vascular disease

More articles from Life Sciences:

nachricht The balancing act: An enzyme that links endocytosis to membrane recycling
07.12.2016 | National Centre for Biological Sciences

nachricht Transforming plant cells from generalists to specialists
07.12.2016 | Duke University

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

NTU scientists build new ultrasound device using 3-D printing technology

07.12.2016 | Health and Medicine

The balancing act: An enzyme that links endocytosis to membrane recycling

07.12.2016 | Life Sciences

How to turn white fat brown

07.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>